Condition: Ovarian Cancer · Cervical Cancer · Sponsor: Shandong University
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).
This description comes directly from the study's public registry record.
Limei Wang · 18560081708 · 18560081708@163.com
Always discuss trial participation with your own doctor first.
| Xiangya Hospital, Central South University, | Changsha, Hunan, China | Not Yet Recruiting |
| Zhongda Hospital, School of Medicine, Southeast University | Nanjing, Jiangsu, China | Not Yet Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
| Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, | Qingdao, Shandong, China | Not Yet Recruiting |
| Shanxi Provincial Cancer Hospital | Taiyuan, Shanxi, China | Not Yet Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06251947